| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.09. | Integrum AB: The board of Integrum appoints Scott Flora as acting CEO | 105 | GlobeNewswire (Europe) | Integrums CEO Rickard Brånemark has today agreed together with the board that he will leave the CEO role. The board announces that Scott Flora, board member since 2023, has been appointed acting CEO... ► Artikel lesen | |
| 15.09. | MacroGenics, Inc.: MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 | 219 | GlobeNewswire (Europe) | Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing... ► Artikel lesen | |
| 15.09. | Replimune Group Inc: Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 | 132 | GlobeNewswire (Europe) | Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1... ► Artikel lesen | |
| 15.09. | Lantheus Holdings, Inc.: Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 | 156 | GlobeNewswire (Europe) | Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete... ► Artikel lesen | |
| 15.09. | 23andMe, Inc.: 23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study | 144 | GlobeNewswire (Europe) | 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics... ► Artikel lesen | |
| 15.09. | 23andMe, Inc.: 23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial | 83 | GlobeNewswire (Europe) | 23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and... ► Artikel lesen | |
| 15.09. | MAX Power Mining Corp. Announces Results of Annual General and Special Meeting | 362 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) ("MAX Power" or the "Company") announces the results of its annual general... ► Artikel lesen | |
| 15.09. | Ipsen Pharma: Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis | 553 | GlobeNewswire (Europe) | Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| SUPER MICRO COMPUTER | 2.941 |
| EVOTEC | 2.193 |
| TUI | 1.880 |
| BAYER | 1.811 |
| NVIDIA | 1.701 |
| NEL | 1.305 |
| RENK GROUP | 1.162 |
| RHEINMETALL | 1.061 |
| TESLA | 887 |
| PALANTIR TECHNOLOGIES | 839 |
| DEUTSCHE BANK | 788 |
| VOLKSWAGEN | 768 |
| MICROSTRATEGY | 728 |
| BYD | 710 |
| PLUG POWER | 676 |
| COMMERZBANK | 670 |
| BASF | 645 |
| JINKOSOLAR | 624 |
| MERCEDES-BENZ | 603 |
| AMAZON | 588 |
| DEUTSCHE TELEKOM | 570 |
| INTEL | 562 |
| BMW | 557 |
| ALLIANZ | 549 |
| THYSSENKRUPP | 548 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
